This article is more than 5 years old. Information may no longer be current.

Pieris, Allergan to develop Anticalins for treating ocular disorders

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

FREISING-WEIHENSTEPHAN, Germany — Pieris has entered into a collaboration agreement with Allergan to develop Anticalins for treating serious ocular disorders, Pieris announced in a press release.

Anticalins are a novel class of lipocalin-based drugs that are engineered to bind, store and transport disease-relevant targets, including lipids and hormones, with high affinity and specificity, according to the release.

Under the terms of the agreement, Pieris and Allergan will work together to optimize Pieris' existing lead Anticalins and to design new Anticalins for ophthalmic indications.

In exchange for an upfront payment of $10 million, Pieris has granted Allergan an exclusive worldwide license for specific Anticalins to be used in the field, the release said. Allergan will be accountable for all costs associated with discovery, development, and commercialization.

Full financial terms of the agreement have not yet been disclosed.